asthma news from FierceBiotech

Transcription Factor Therapeutics has licensed the worldwide rights to Anesiva's NF-kB Decoy program, which includes the clinical drug candidate Avrina. NF-kB Transcription Factor Decoy inhibits Read more...

Recruiting the right number of the right patients for any clinical trial can be a tough prospect. Now there are a host of new efforts to match a patient with a clinical trial, including a service Read more...

Critical Therapeutics is merging with Cornerstone Read more...

GlaxoSmithKline has agreed to pay Amira Pharmaceuticals up to $425 million for the exclusive worldwide rights to its FLAP inhibitors, including AM103 and other compounds within the current Read more...

Teva buys CoGenesys for $400M DEALS WHO WITH WHAT SCOOP Pfizer Washington Read more...

Continuing the hot trend of biopharma companies partnering with research institutions, Pfizer has Read more...

Canada's Topigen Pharmaceuticals has gained $25 million in venture support for its clinical programs in respiratory disorders. The round brings the biotech's total financing to $71 million to date. Read more...

Press Release: AtheroGenics to Present at JPMorgan Healthcare Conference

Read more...

Isis Pharmaceuticals has made a deal to sell $75 million in common stock to fund its clinical development programs. Azimuth Opportunity will buy the stock over 18 months at a slight discount. Much of that money will go to fund preclinical trials in diabetes, asthma and cardiovascular conditions. Report

The UK's SkyePharma has inked a $165 million licensing deal ($25 million of which is up front) with Kos Pharmaceuticals for the U.S. marketing rights to Flutiform for asthma, its lead drug candidate. It's good news for SkyePharma, which has been seeking a partner on the drug for three years. The biotech company saw its shares surge on the news, even though some analyst's enthusiasm for the deal was tempered by the fact that SkyePharma hadn't landed a larger partner for the drug. Flutiform …

Read more...